Immunome, Inc.

About Immunome, Inc.

Immunome is a clinical-stage oncology company focused on improving outcomes for cancer patients by developing and expanding a portfolio of first-in-class and best-in-class therapeutic candidates. They integrate exacting science with a patient-centric approach to address high unmet needs in cancer therapy.

Products & Services

Varegacestat (AL102):A gamma secretase inhibitor in Phase 3 trials for the treatment of desmoid tumors.

IM-1021:A ROR1-targeted antibody-drug conjugate (ADC) in Phase 1 trials.

IM-3050:A FAP-targeted radioligand therapy (RLT) with recent IND clearance.

IM-1617:A preclinical ADC targeting an undisclosed target with expression in multiple solid tumors.

IM-1340:A preclinical antibody-drug candidate targeting an undisclosed target.

IM-1335:A preclinical ADC targeting solid tumors.

Specialties

Antibody-Drug Conjugates (ADCs) Radioligand Therapies (RLT) Cancer Therapy Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 400000000 MR: - FA: approximately $400 million FAN: 400000000	D: 2025-12-16 FD: 2025-12-16	7 investors
2	RT: Public Offering T: - FT: Public Offering	A: 400000000 MR: - FA: $400 million FAN: 400000000	D: 2025-12-15 FD: 2025-12-15	7 investors
3	RT: Public Offering T: - FT: Public Offering	A: 150000000 MR: - FA: $150.0 million FAN: 150000000	D: 2025-01-31 FD: 2025-01-31	5 investors
4	RT: Public Offering T: - FT: Public Offering	A: 172500000 MR: - FA: $172.5 million FAN: 172500000	D: 2025-01-31 FD: 2025-01-31	5 investors
5	RT: Public Offering T: - FT: Public Offering	A: 125000000 MR: - FA: $125.0 million FAN: 125000000	D: 2025-01-29 FD: 2025-01-29	5 investors
6	RT: Public Offering T: - FT: Public Offering	A: 230000000 MR: - FA: $230.0 million FAN: 230000000	D: 2024-02-16 FD: 2024-02-16	5 investors
7	RT: Public Offering T: - FT: Public Offering	A: 200000000 MR: - FA: $200.0 million FAN: 200000000	D: 2024-02-13 FD: 2024-02-13	5 investors
8	RT: Public Offering of Common Stock T: - FT: Public Offering of Common Stock	A: 200000000 MR: - FA: $200.0 million FAN: 200000000	D: 2024-02-13 FD: 2024-02-13	5 investors

Public Offering Latest

2025-12-16

$400.0M

7 investors (Pro only)

Public Offering 2025-12-15

$400.0M

Public Offering 2025-01-31

$150.0M

View 7 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Clay Siegall

President & Chief Executive Officer

J

Jack Higgins

Chief Scientific Officer

K

Kinney Horn

Chief Business Officer

B

Bob Lechleider

Chief Medical Officer

M

Max Rosett

Chief Financial Officer

R

Roee Shahar

EVP, Commercial

View 5 more team members with Pro

Unlock Full Team Directory

Recent News

Immunome, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised